Can you share with us a specific patient who has had an ACS event and is post-PCI, and how you optimize CV risk reduction in the age of PCSK9-mediated LDL-C risk reduction and aggressive LDL-C lowering?

Can you share with us a specific patient who has had an ACS event and is post-PCI, and how you optimize CV risk reduction in the age of PCSK9-mediated LDL-C risk reduction and aggressive LDL-C lowering?

CLICK HERE FOR CME CREDIT

Can you share with us a specific patient who has had an ACS event and is post-PCI, and how you optimize CV risk reduction in the age of PCSK9-mediated LDL-C risk reduction and aggressive LDL-C lowering?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Dan Atar, MD

Dan Atar, MD

Head of Research Oslo University Hospital Ulleval Professors of Cardiology University of Oslo Oslo, Norway Visiting Associate Professorship Johns Hopkins University Baltimore, Maryland